Cyclopharm Limited (CYC) Price & Analysis

Compare

17 Followers

CYC Stock Chart & Stats

AU$0.98

-AU$0.04(-1.82%)

At close: Jan 09 4:00 PM EST

AU$0.98

-AU$0.04(-1.82%)

Day’s Range― - ―

52-Week RangeAU$0.56 - AU$2.44

Previous CloseN/A

Volume20.15K

Average Volume (3M)97.64K

Market Cap

AU$130.03M

Enterprise ValueAU$102.26M

Total Cash (Recent Filing)AU$12.41M

Total Debt (Recent Filing)AU$7.98M

Price to Earnings (P/E)―

Beta0.26

Next Earnings

Feb 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding111,136,850

10 Day Avg. Volume155,345

30 Day Avg. Volume97,642

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)3.83

Price to Sales (P/S)5.93

P/FCF Ratio-12.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumable RevenueCyclopharm's core revenue is recurring consumable sales tied to each patient study. This creates a predictable, usage-driven revenue stream that scales with procedure volumes and the installed base, supporting durable top-line cash inflows as clinical adoption persists.

Installed Base Driving Future DemandEquipment sales expand the installed base of Technegas generators, creating long-term follow-on consumable demand and service opportunities. A growing installed base makes revenue more durable and helps lock customers into the Technegas ecosystem over multiple years.

Low Financial LeverageCyclopharm's low leverage and high equity ratio provide financial flexibility to withstand near-term earnings pressures, fund strategic initiatives, and invest in commercial expansion without heavy debt servicing, supporting stability over the medium term.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow reduces internal funding for R&D, marketing and service expansion. Over months, this constrains reinvestment, increases reliance on external financing, and limits the firm's ability to scale its installed base organically.

Persistent Net Losses And Negative EBITOngoing losses and negative EBIT indicate the business has not yet translated revenue growth into profitability. Without margin improvement, persistent deficits will pressure reserves and could force cost cuts or dilute shareholders to sustain operations.

Operational Efficiency ChallengesDespite modest revenue growth, the lack of positive net income highlights inefficiencies in cost structure or pricing. Over 2-6 months, failure to improve margins limits free cash flow conversion and weakens the economics of scaling the consumable/equipment model.

Cyclopharm Limited News

Cyclopharm Launches Placement and SPP to Fund Growth

The latest announcement is out from Cyclopharm Limited ( ($AU:CYC) ). Cyclopharm plans to issue up to 14.7...

1d ago

CYC

Cyclopharm Outlines Terms of Confidential Institutional Share Placement

Cyclopharm Limited ( ($AU:CYC) ) has issued an announcement. Cyclopharm Limited has released an investor presentation in connection...

1d ago

CYC

Cyclopharm Raises A$14m and Launches A$2m SPP to Accelerate US Technegas Rollout

Cyclopharm Limited ( ($AU:CYC) ) has shared an announcement. Cyclopharm Limited has raised A$14 million via a placement...

1d ago

CYC

Cyclopharm Posts Record FY2025 Revenue as U.S. Technegas Sales Surge but Loss Widens on Growth Investment

Cyclopharm Limited ( ($AU:CYC) ) has provided an update. Cyclopharm has reported record unaudited FY2025 operating revenue of...

3d ago

CYC

Cyclopharm Shares Halted Ahead of Capital Raising Announcement

Cyclopharm Limited ( ($AU:CYC) ) has provided an announcement. Cyclopharm Limited has requested and been granted a trading...

3d ago

CYC

Cyclopharm Backs AI-Enabled COPD Trial to Expand Reach of Technegas Lung Imaging

Cyclopharm Limited ( ($AU:CYC) ) has issued an update. Cyclopharm has entered into a clinical research collaboration with...

7d ago

CYC

Technegas Named Preferred Ventilation Agent in Key US and Global Lung Imaging Guideline

Cyclopharm Limited ( ($AU:CYC) ) has issued an announcement. Cyclopharm’s flagship lung imaging agent Technegas has been explicitly...

9d ago

CYC

Cyclopharm Secures Insurer Indemnity in 4DMedical Legal Dispute

An update from Cyclopharm Limited ( ($AU:CYC) ) is now available. Cyclopharm Limited has confirmed that its insurer...

9d ago

CYC

Cyclopharm Secures First U.S. Children’s Hospital Adoption of Technegas

Cyclopharm Limited ( ($AU:CYC) ) has issued an announcement. Cyclopharm Limited has signed an agreement with Stanford Medicine...

24d ago

CYC

Cyclopharm Wins Colombian Approval for Technegas, Extending Global Lung Imaging Footprint

Cyclopharm Limited ( ($AU:CYC) ) has shared an update. Cyclopharm Limited has secured regulatory approval for its Technegas...

2M ago

CYC

CYC FAQ

What was Cyclopharm Limited’s price range in the past 12 months?

Cyclopharm Limited lowest share price was AU$0.56 and its highest was AU$2.44 in the past 12 months.

What is Cyclopharm Limited’s market cap?

Cyclopharm Limited’s market cap is AU$130.03M.

When is Cyclopharm Limited’s upcoming earnings report date?

Cyclopharm Limited’s upcoming earnings report date is Feb 25, 2026 which is in 20 days.

How were Cyclopharm Limited’s earnings last quarter?

Cyclopharm Limited released its earnings results on Aug 27, 2025. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.

Is Cyclopharm Limited overvalued?

According to Wall Street analysts Cyclopharm Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyclopharm Limited pay dividends?

Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here

What is Cyclopharm Limited’s EPS estimate?

Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyclopharm Limited have?

Cyclopharm Limited has 111,136,850 shares outstanding.

What happened to Cyclopharm Limited’s price movement after its last earnings report?

Cyclopharm Limited reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.498%.

Which hedge fund is a major shareholder of Cyclopharm Limited?

Currently, no hedge funds are holding shares in AU:CYC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cyclopharm Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-31.98%

Trailing 12-Months

Asset Growth

-12.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cyclopharm Limited

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.